Clinical trials: Experimental Group
Hearing Loss
Evaluation of New Fitting Characteristics for Extended Wear Hearing Aid Technology
Two groups of hearing aid candidates will be fit with extended wear technology. One group will be fit with the commercially available models, and the other group will be fit with either the commercially available model or a new…
- Trial name
- NCT05274165
- Testing
- Lyric Hearing Aid- Experimental Design, Lyric Hearing Aid- Commercially Available
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Sonova AG
NSCLC
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
This is a multicenter, open-label, phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and antitumor efficacy of IN10018 in combination with third-generation EGFR-TKI (Furmonertinib is the proposed)…
- Trial name
- NCT05994131
- Testing
- IN10018, Furmonertinib
- Where
- China
- Volunteers
- 110 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Pain, Anxiety
Effect of Playing an Audio Clip for Pain and Anxiety Control in Patients While Dressing Burn Wounds
The aim of this clinical trial is to assess the effect of playing patient preferred audio clip for controlling the pain and anxiety in patients while dressing burn wounds.
- Trial name
- NCT05515302
- Testing
- Audio Clip
- Where
- Qatar
- Volunteers
- 100 people
- Sponsor
- Hamad Medical Corporation
Hip Osteoarthritis
OXINIUM◊ DH Total Hip Arthroplasty Pivotal Study
The purpose of this study is to monitor safety of the participants implanted with the OXINIUM◊ DH Hip System up to 10-years post-implantation
- Trial name
- NCT02353377
- Testing
- OXINIUM DH Hip System, BIOLOX◊
- Volunteers
- 413 people
- Sponsor
- Smith & Nephew, Inc.
Tinea Pedis
A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis
The study is being done to determine and compare the safety and effectiveness of an investigational combination therapy (low and high concentrations) versus mono-therapy (low and high concentrations) or mono-therapy (fixed…
- Trial name
- NCT03897257
- Testing
- UHE-103A1 cream, UHE-103A2 cream, UHE-103B cream
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 240 people
- Sponsor
- Therapeutics, Inc.
Retinopathy of Prematurity (ROP)
Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)
The main purpose of this study is to evaluate the long-term efficacy and safety outcomes following short-term exposure to rhIGF-1/rhIGFBP-3 versus standard neonatal care in Study ROPP-2008-01 (NCT01096784).
- Trial name
- PEDAL (NCT02386839)
- Testing
- rhIGF-1/rhIGFBP-3
- Where
- 16 sites in United States, Italy and 4 more
- Volunteers
- 76 people
- Sponsor
- Shire
Osteoarthritis, Traumatic Arthritis
Prospective Multicenter Post Approval Study of the LPS-Flex Mobile Bearing Knee
The purpose of the study is to assess the long-term performance of the NexGen LPS-Flex Mobile Bearing Knee in the treatment of patients with severe knee pain or degenerative knee disease.
- Conditions
- Osteoarthritis, Traumatic Arthritis, Avascular Necrosis of the Femoral Condyle, Moderate Varus
- Trial name
- NCT00854295
- Testing
- NexGen LPS-Flex Mobile Bearing Knee
- Where
- 3 sites in United States
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- Zimmer Biomet
Uterine Cervical Neoplasia, Cervix Intraepithelial Neoplasia
Safety and Efficacy Study of Antiviral Local Application to Treat High Grade Cervical Intraepithelial Lesions (CIN2/3)
The purpose of this phase-II study is to evaluate the efficacy and safety of an aqueous gel containing an antiviral, administered directly on cervix exhibiting high grade squamous or glandular intraepithelial lesion (CIN 2 and 3)…
- Trial name
- Colvir-PhaseII (NCT01303328)
- Testing
- C1
- Where
- 9 sites in Belgium
- Volunteers
- 200 people
- Sponsor
- Mithra Pharmaceuticals
COVID-19 Respiratory Infection, COVID-19
Efficacy and Safety Study of Essential Oil-Based Preparation Administered to COVID-19 Patients
The aim of this study was to compare the efficacy and safety of the essential oil-based product in patients with mild to moderate symptomatic COVID-19 Positive infection confirmed by PCR.
- Trial name
- NCT06452069
- Testing
- IMMUNO19
- Where
- 10 sites in Turkey (Türkiye)
- Volunteers
- 280 people
- Sponsor
- Biodex S.A
Healthy Volunteers
Study on the Mass Balance of [14C] CMS-D002 in Healthy Adult Participants in China
This phase 1, single-group study will evaluate the mass balance of [14C] CMS-D002 after a single oral dose in healthy adult participants in China.
- Trial name
- NCT07788482
- Testing
- [14C] CMS-D002
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.
Healthy Participants
A Single- and Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2059 Powder for Inhalation
Randomized, double-blind and placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetic characteristics of SYH2059 powder for inhalation after single and multiple doses in healthy subjects.
- Trial name
- NCT07510958
- Testing
- SYH2059
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- InnovStone Therapeutics Limited
Knee Osteoarthritis
Clinical Investigation to Compare the Safety and Efficacy of Cellular Matrix to Those of Ostenil® Plus and to Those of PRP Only
Platelet-rich plasma (PRP) is an autologous product prepared from the patient's own blood, representing a powerful source of platelet-derived growth factors, particularly useful in the field of regenerative medicine.
- Trial name
- NCT02964143
- Testing
- Cellular Matrix / A-CP HA, Ostenil® Plus, RegenKit-BCT-1
- Volunteers
- 306 people
- Sponsor
- Regen Lab SA
Respiratory Disorders
Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' NTHi candidate vaccine in adults, administered for the first time in humans.
- Trial name
- NCT01657526
- Testing
- GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A), GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Fat Reduction
Non-Invasive Reduction of Abdominal Fat
This study is being performed to reduce unwanted abdominal fat using a new applicator for the Zeltiq System.
- Trial name
- JUNO (NCT01101997)
- Testing
- The Zeltiq System
- Where
- 5 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Atrial Fibrillation, Obstructive Sleep Apnea
The Efficacy of PAP Therapy on Reducing AF Recurrence in Patients With Morbidity of OSA
This study aims to test the effectiveness of positive airway pressure therapy on reducing clinical failure after rhythm control treatment and restoring with regular heart beat in atrial fibrillation patients with obstructive…
- Trial name
- AFOSA (NCT04519489)
- Testing
- PAP therapy with telemonitoring, AF standard management and OSA general care
- Where
- 2 sites in China
- Volunteers
- 129 people
- Sponsor
- Philips (China) Investment CO., LTD
COVID-19
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination to evaluate safety and immunogenicity in healthy population aged 18 years old and above.
- Trial name
- NCT05911048
- Testing
- Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C), Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above
The aim of this study is to assess the immunogenicity, safety and reactogenicity of the RSV PreFusion protein 3 older adult (RSVPreF3 OA) investigational vaccine when co-administered with an adjuvanted quadrivalent influenza (FLU…
- Trial name
- NCT05568797
- Testing
- RSVPreF3 OA vaccine, FLU vaccine
- Where
- 37 sites in Belgium, Finland and 3 more
- Volunteers
- 1,045 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Non-squamous Non-small Cell Lung Cancer
Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer
The objective of this study is to assess the similarity between QL1101 and Avastin® respectively combined with chemotherapy in terms of efficacy and safety in patients with non-squamous non-small cell lung cancer.
- Trial name
- NCT03169335
- Testing
- QL1101, Avastin®, Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 535 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Poliomyelitis
A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants
The purpose of the study is to evaluate safety and immunogenicity of inactivated poliomyelitis vaccine based on Sabin strain (LBVC) in healthy infants to select optimal dose of LBVC as well as to demonstrate the lot-to-lot…
- Trial name
- NCT03169725
- Testing
- Inactivated Poliomyelitis Vaccine (Sabin strain), Inactivated Poliomyelitis Vaccine (Salk strain)
- Where
- 3 sites in Philippines, Thailand
- Volunteers
- 1,417 people, healthy volunteers welcome
- Sponsor
- LG Chem
Healthy Volunteers
A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy Volunteers
This is a randomized open comparative parallel group study of the safety and pharmacokinetics of GNR-068 and Stelara® in healthy volunteers. Participants received a single subcutaneous dose of ustekinumab 45 mg.
- Trial name
- NCT06481215
- Testing
- GNR-068, Stelara®
- Where
- 2 sites in Russia
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- AO GENERIUM
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.